ENCUBE
GenericsENCUBE is a generic drug manufacturer focused on Dermatology, Oncology, Immunology.
ENCUBE's Key Drugs
ENCUBE's core commercial portfolio centers on ADAPALENE AND BENZOYL PEROXIDE, TRETINOIN MICROSPHERE, CLINDAMYCIN PHOSPHATE AND TRETINOIN, spanning Dermatology and Oncology — its most strategically important drugs approved in the last 15 years.
ENCUBE's Recent FDA Approvals
New NDA/BLA approvals for ENCUBE over the last two years — novel drugs only, excluding generics and label supplements.
ENCUBE's Therapeutic Areas
ENCUBE's approved drugs and pipeline span 5 therapeutic areas, led by Dermatology and Oncology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ENCUBE's Top Competitors
ENCUBE's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Pfizer, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ENCUBE Pipeline Snapshot
Active clinical trials for ENCUBE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ADAPALENE AND BENZOYL PEROXIDE leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Dermatology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1993-07-16
- Latest
- 2026-05-18
- Applications
- 70